Emer­gent to de­liv­er a $120M con­tract for the small­pox vac­cine for the US stock­pile

Emer­gent BioSo­lu­tions, a vac­cine and ther­a­peu­tic man­u­fac­tur­er for de­fense pur­pos­es, is ce­ment­ing its small­pox vac­cine pro­duc­tion sta­tus by ink­ing a con­tract with the US gov­ern­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER